1. Circulating biomarkers of the CS4P and CLIP scores are not altered in a pig model of acute cardiogenic shock and additional short-term circulatory support.
- Author
-
Riehle C, Sieweke JT, Udesen NLJ, Helgestad OKL, Froese N, Ravn HB, Lichtinghagen R, Møller JE, Bauersachs J, and Schäfer A
- Subjects
- Humans, Animals, Swine, Shock, Cardiogenic diagnosis, Shock, Cardiogenic therapy, Shock, Cardiogenic etiology, Cardiac Output, Biomarkers, Treatment Outcome, Myocardial Infarction, Heart-Assist Devices adverse effects
- Abstract
Background: Cardiogenic shock (CS) is the leading cause of death in patients with myocardial infarction with a mortality rate greater than 50%. Recently, the CS 4 Proteins (CS4P) and CLIP scores have been developed to predict survival in CS patients. However, their impact in acute CS and additional short-term left ventricular (LV) circulatory support as prognostic markers is currently not known., Methods and Results: CS was induced in a porcine model by injecting microsphere particles into the left main coronary artery. Mechanical circulatory support was performed by additional percutaneous LV unloading using an Impella microaxial flow-pump for 30 minutes. Serum samples were collected at baseline, following the onset of CS, and additional LV unloading. Serum levels of biomarkers of the CS4P (beta-2-microglobulin, ALDOB, L-FABP, SerpinG1) and the CLIP scores (Cystatin C, Lactate, Interleukin-6, NT-proBNP) were neither different at any time point investigated nor did they correlate with cardiac output., Conclusion: The CS4P and CLIP scores do not reflect immediate whole-body dysregulation in acute CS and have not been able to predict the potential reversal following additional short-term mechanical support by LV unloading in our experimental model. The impact of both scores as prognostic markers after the immediate onset of CS and following additional short-term LV unloading to identify patients at greatest risk remains to be determined., Competing Interests: Declaration of competing interest CR received travel support from Abiomed. NLJU, JB, and AS received research support from Abiomed. OKLH received research support and consultant compensation from Abiomed. JEM received institutional research grant support from Abiomed and Novo Nordisk Foundation, and travel support from Abiomed. The remaining authors report no conflict of interest., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF